menu
    • menu
    [{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China National Medical Products Administration Approves Gilead's Truvada\u00ae for HIV Pre-Exposure Prophylaxis (PrEP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA\u00ae and ATRIPLA\u00ae Tablets in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces Investigational Injectable Cabotegravir is Superior to Oral Standard of Care for HIV Prevention in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Gets Breakthrough Therapy Designation for Investigational, Long-Acting Cabotegravir for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbutus and Antios Therapeutics Announce Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 Hep B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Antios Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to ViiV Healthcare\u2019s New Drug Application For Cabotegravir Long-Acting for Prevention Of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"AB-729","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Clevudine Monophosphate Prp","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JNJ-73763989","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ATI-2173","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."}]

    Find Clinical Drug Pipeline Developments & Deals for Tenofovir Disoproxil

    Menu

    Tenofovir Disoproxil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India arrow
                            CPhI Worldwide, Milan
                            Booth #5C33
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

                            Details : Stride's Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 15, 2021

                            Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and AT...

                            Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.

                            Brand Name : ATI-2173

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 25, 2022

                            Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Arrowhead Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JNJ-73763989,Tenofovir Disoproxil Fumarate,Tenofovir Alafenamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

                            Details : JNJ-3989 is a sub-cutaneous, ribonucleic acid interference (RNAi) therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside a...

                            Brand Name : JNJ-3989

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 01, 2022

                            Lead Product(s) : JNJ-73763989,Tenofovir Disoproxil Fumarate,Tenofovir Alafenamide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clevudine Monophosphate Prp,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

                            Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.

                            Brand Name : ATI-2173

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : Clevudine Monophosphate Prp,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Antios Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate,AB-729

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : GordonMD Global Investments

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

                            Details : The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.

                            Brand Name : ATI-2173

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 03, 2021

                            Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate,AB-729

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : GordonMD Global Investments

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ViiV Healthcare

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed

                            ViiV Healthcare

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Priority Review to ViiV Healthcare’s New Drug Application For Cabotegravir Long-Acting for Preven...

                            Details : The NDA was based on the results from two phase IIb/III studies, HPTN 083 and HPTN 084, which evaluated the safety and efficacy of cabotegravir long-acting for PrEP in men who have sex with men, transgender women, and cisgender women use in HIV preventio...

                            Brand Name : Cabenuva

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2021

                            Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arbutus Biopharma

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Arbutus Biopharma

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-729,ATI-2173,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Antios Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arbutus and Antios Therapeutics Announce Collaboration Agreement to Evaluate AB-729 in Combination with ATI-21...

                            Details : The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of the combination of ATI-2173, AB-729 and Viread.

                            Brand Name : GalNAc-RNAi

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : AB-729,ATI-2173,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Antios Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lupin Ltd

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dolutegravir Sodium,Lamivudine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD...

                            Details : Lupin has received tentative approval from the United States FDA under the U.S. President’s Emergency Plan for AIDS Relief for its NDA for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate Tablets, 50 mg/300 mg/300 mg, and antiretroviral Fixed D...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 30, 2021

                            Lead Product(s) : Dolutegravir Sodium,Lamivudine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lupin Ltd

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

                            Details : Lupin has received approval from the United States Food and Drug Administration (USFDA) to market its Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg. The drugs are indicated in combination with other antiretroviral agents for HIV-...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2021

                            Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ViiV Healthcare

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed

                            ViiV Healthcare

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ViiV Healthcare Gets Breakthrough Therapy Designation for Investigational, Long-Acting Cabotegravir for HIV Pr...

                            Details : The breakthrough therapy designation is based on efficacy and safety results from HPTN 083, a phase IIb/III clinical trial that compared long-acting, injectable cabotegravir to daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg for ...

                            Brand Name : Vocabria

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2020

                            Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate,Emtricitabine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth